Literature DB >> 26246292

Once-daily aminoglycoside dosing: An update on current literature.

Matthew S Stankowicz1, Jad Ibrahim2, Daniel L Brown2.   

Abstract

PURPOSE: The advantages and disadvantages of once-daily versus conventional dosing of aminoglycoside antibiotics are reviewed.
SUMMARY: Although administration of multiple daily doses remains the standard method of aminoglycoside dosing, once-daily dosing may provide enhanced clinical efficacy and reduced toxicity in selected patient populations; demonstrated pharmacokinetic and pharmacodynamic advantages include enhanced postantibiotic effect and an increased likelihood of a high ratio of serum peak concentration to minimum inhibitory concentration. Published evidence identified in a MEDLINE search covering the period 1985-2014 indicates that once-daily high-dose aminoglycoside therapy generally provides clinical effectiveness equivalent or superior to that of multiple-daily dosing. The risk of nephrotoxicity appears to be comparable with once- and multiple-daily aminoglycoside dosing. Several nomograms have been developed to facilitate once-daily dosing; the Hartford nomogram (using a dose of 7 mg/kg) is the most extensively tested and generally considered the most reliable. However, although those nomograms are convenient to use and may reduce expenses, a daily dosing regimen determined by individualized pharmacokinetic monitoring is likely to be more effective for achieving specific serum concentrations and may be a preferable approach for some patients. Patients who are pregnant or have liver failure, severe renal insufficiency, serious illness, or nutritional deficiency are not appropriate candidates for once-daily dosing.
CONCLUSION: Once-daily aminoglycoside dosing is an effective, well-established method to achieve therapeutic efficacy while limiting the risk of toxicity and simplifying the processes of dosing and monitoring.
Copyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26246292     DOI: 10.2146/ajhp140564

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.

Authors:  Joran Elie Michiels; Bram Van den Bergh; Natalie Verstraeten; Maarten Fauvart; Jan Michiels
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.

Authors:  Tomefa E Asempa; Joseph L Kuti; Julie D Seroogy; Allison S Komirenko; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit.

Authors:  Jacob P Counts; Jessica L Elefritz; Erica E Reed; Marilly Palettas; Connor Aossey; Julia J Beatty
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-01-14       Impact factor: 2.441

Review 5.  Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review.

Authors:  Vinod Krishnappa; Mohit Gupta; Gurusidda Manu; Shivani Kwatra; Osei-Tutu Owusu; Rupesh Raina
Journal:  Int J Nephrol       Date:  2016-11-03

6.  Standards of aminoglycoside therapeutic drug monitoring in a South African private hospital: perspectives and implications.

Authors:  Mariette du Toit; Johanita R Burger; Dorcas M Rakumakoe; Malie Rheeders
Journal:  Ghana Med J       Date:  2019-03

7.  Model Re-Estimation: An Alternative for Poor Predictive Performance during External Evaluations? Example of Gentamicin in Critically Ill Patients.

Authors:  Alexandre Duong; Chantale Simard; David Williamson; Amélie Marsot
Journal:  Pharmaceutics       Date:  2022-07-07       Impact factor: 6.525

8.  Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates.

Authors:  Collin Z Yu; Scott R Myers; Jonathan D Faldasz
Journal:  Pediatr Infect Dis J       Date:  2020-04       Impact factor: 3.806

9.  Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.

Authors:  Tomás Sou; Jon Hansen; Edgars Liepinsh; Maria Backlund; Onur Ercan; Solveiga Grinberga; Sha Cao; Paraskevi Giachou; Anna Petersson; Magdalena Tomczak; Malgorzata Urbas; Dorota Zabicka; Carina Vingsbo Lundberg; Diarmaid Hughes; Sven N Hobbie; Lena E Friberg
Journal:  Clin Pharmacol Ther       Date:  2020-11-28       Impact factor: 6.875

10.  Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.

Authors:  Jessica R Tait; Hajira Bilal; Kate E Rogers; Yinzhi Lang; Tae-Hwan Kim; Jieqiang Zhou; Steven C Wallis; Jürgen B Bulitta; Carl M J Kirkpatrick; David L Paterson; Jeffrey Lipman; Phillip J Bergen; Jason A Roberts; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antibiotics (Basel)       Date:  2022-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.